Santhera Pharmaceuticals Holding AG (SANN) - Financial and Strategic SWOT Analysis Review

Date: June 4, 2014
Pages: 37
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S51F5C26C17EN
Leaflet:

Download PDF Leaflet

Santhera Pharmaceuticals Holding AG (SANN) - Financial and Strategic SWOT Analysis Review
Santhera Pharmaceuticals Holding AG (SANN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Santhera Pharmaceuticals Holding AG (Santhera) is a pharmaceutical company. It focuses on the development and commercialization of novel pharmaceutical products indicated for the treatment of neuromuscular and mitochondrial diseases. The company’s lead product candidate, Catena/Raxone is being developed for the treatment of Leber's hereditary optic neuropathy (submitted for marketing authorization in Europe); Duchenne muscular dystrophy (Phase III); and primary progressive multiple sclerosis (Phase II).

Santhera Pharmaceuticals Holding AG Key Recent Developments

Apr 08, 2014: Santhera Reports Financial Figures for 2013 and Progress towards Turnaround
Mar 19, 2014: Santhera Receives US Patent for Fipamezole in the Treatment of Neurodegenerative Diseases
Aug 30, 2013: Santhera Successfully Concludes Restructuring in First Half Year of 2013

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research. Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Santhera Pharmaceuticals Holding AG - Key Facts
Santhera Pharmaceuticals Holding AG - Key Employees
Santhera Pharmaceuticals Holding AG - Key Employee Biographies
Santhera Pharmaceuticals Holding AG - Major Products and Services
Santhera Pharmaceuticals Holding AG - Pharmaceutical Pipeline Products Data
Santhera Pharmaceuticals Holding AG, Pipeline Products by Therapy Area
Santhera Pharmaceuticals Holding AG, Pipeline Products by Development Phase
Santhera Pharmaceuticals Holding AG - History
Santhera Pharmaceuticals Holding AG - Company Statement
Santhera Pharmaceuticals Holding AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Santhera Pharmaceuticals Holding AG - Business Description
Santhera Pharmaceuticals Holding AG - SWOT Analysis
SWOT Analysis - Overview
Santhera Pharmaceuticals Holding AG - Strengths
Strength - Strong Research and Development Capabilities
Strength - Lead Product Catena
Santhera Pharmaceuticals Holding AG - Weaknesses
Weakness - History of Operating Losses
Weakness - Discontinuation of Catena’s Sales in Canada
Weakness - Lack of Manufacturing Facilities
Santhera Pharmaceuticals Holding AG - Opportunities
Opportunity - Growth Potential: Orphan Drugs
Opportunity - Strategic Initiatives
Opportunity - Changing Demographics
Santhera Pharmaceuticals Holding AG - Threats
Threat - Competitive Pressures
Threat - Stringent Government Regulations
Threat - Uncertain R&D Outcomes
Santhera Pharmaceuticals Holding AG - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
Santhera Pharmaceuticals Holding AG, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 08, 2014: Santhera Reports Financial Figures for 2013 and Progress towards Turnaround
Aug 30, 2013: Santhera Successfully Concludes Restructuring in First Half Year of 2013

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Santhera Pharmaceuticals Holding AG, Key Facts
Santhera Pharmaceuticals Holding AG, Key Employees
Santhera Pharmaceuticals Holding AG, Key Employee Biographies
Santhera Pharmaceuticals Holding AG, Major Products and Services
Santhera Pharmaceuticals Holding AG, Number of Pipeline Products by Therapy Area
Santhera Pharmaceuticals Holding AG, Number of Pipeline Products by Development Stage
Santhera Pharmaceuticals Holding AG, Pipeline Products By Therapy Area and Development Phase
Santhera Pharmaceuticals Holding AG, History
Santhera Pharmaceuticals Holding AG, Subsidiaries
Santhera Pharmaceuticals Holding AG, Key Competitors
Santhera Pharmaceuticals Holding AG, Ratios based on current share price
Santhera Pharmaceuticals Holding AG, Annual Ratios
Santhera Pharmaceuticals Holding AG, Interim Ratios
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
Santhera Pharmaceuticals Holding AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Santhera Pharmaceuticals Holding AG, Pipeline Products by Therapy Area
Santhera Pharmaceuticals Holding AG, Pipeline Products by Development Phase
Santhera Pharmaceuticals Holding AG, Performance Chart (2009 - 2013)
Santhera Pharmaceuticals Holding AG, Ratio Charts
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014

Ask Your Question

Santhera Pharmaceuticals Holding AG (SANN) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: